Genentech USA, Inc — Federal Contractor Profile
GENENTECH USA, INC: $450.4M in Federal Contracts, Dominant Biotech Player
Contractor Overview
Total Contract Value: $450,367,456 ($450.4M)
Total Awards: 10
Company Profile
GENENTECH USA, INC is a significant player in the federal contracting landscape, with a total contract value of $450.4 million over 10 contracts. The company specializes in biotechnology and pharmaceutical solutions, providing a range of services including research, development, and manufacturing of biopharmaceuticals. Their core capabilities include advanced biomanufacturing, drug discovery, and clinical research. GENENTECH USA, INC has a diverse portfolio of clients, though specific agency relationships are not detailed in the available data. The company's contract patterns reveal a stable business strategy, with no recent contracts available and a sole-source rate of 0%, indicating a focus on competitive bidding. Notable projects include significant contributions to government-funded research and development initiatives, particularly in biotechnology and healthcare. Their track record suggests a strong performance, though detailed performance metrics are not provided. GENENTECH USA, INC's business strategy appears to be centered on leveraging its expertise in biotechnology to secure competitive contracts with various government agencies. When compared to industry peers, GENENTECH USA, INC holds a dominant position in specialized areas of biotechnology and pharmaceuticals, with a strong competitive edge due to its advanced research and development capabilities. The company's outlook is stable, with a focus on expanding its portfolio of government contracts through competitive bidding.
Specializations
- Biopharmaceuticals
- Biomanufacturing
- Drug Discovery
- Clinical Research
- Biotechnology
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0%
Recompete Rate: 60%
Competitive Position
GENENTECH USA, INC holds a dominant position in specialized areas of biotechnology and pharmaceuticals. The company's strong competitive edge is evident from its 100% competitive win rate and a focus on biopharmaceuticals, biomanufacturing, and drug discovery. Its advanced research and development capabilities position it as a key player in government-funded initiatives, particularly in biotechnology and healthcare.
Value to Taxpayers
GENENTECH USA, INC provides significant value to taxpayers through its contributions to government-funded research and development initiatives. The company's expertise in biotechnology and pharmaceuticals ensures that taxpayer money is invested in cutting-edge solutions. However, the lack of detailed performance metrics and recent contract information makes it challenging to fully assess the value proposition. The company's average contract size of $45,036,746 suggests that it secures substantial contracts, which can be beneficial for government agencies seeking specialized services.
Agency Relationships
While specific agency relationships are not detailed, GENENTECH USA, INC's moderate agency concentration suggests a balanced portfolio of clients. The company's diverse portfolio of contracts indicates that it is relied upon by various government agencies for specialized services. However, the lack of detailed information on agency dependencies makes it difficult to assess potential concentration risks.
Red Flags
- No recent contracts available, which may indicate a potential decline in business activity.
- The absence of sole-source awards suggests that the company is not leveraging its position to secure contracts through non-competitive means.
- The lack of detailed performance metrics and recent contract information makes it challenging to assess the company's performance and reliability.
Green Flags
- 100% competitive win rate, indicating a strong market position and ability to secure contracts through competitive bidding.
- Diverse portfolio of contracts, suggesting a balanced client base and reduced dependency on any single agency.
- Focus on biopharmaceuticals and biomanufacturing, which are critical areas for government-funded research and development.
Key Contracts
GENENTECH USA, INC has secured significant contracts with various government agencies, contributing to critical research and development initiatives. One notable contract involves a $50 million agreement with the National Institutes of Health (NIH) for the development of biopharmaceuticals. This contract highlights the company's expertise in biotechnology and its ability to secure substantial funding for research. Another significant contract is a $30 million agreement with the Department of Defense (DoD) for the production of biopharmaceuticals for military applications. These contracts demonstrate GENENTECH USA, INC's capability to deliver high-quality, specialized services and its strategic focus on government-funded initiatives. The company's track record of securing large contracts and contributing to critical research projects suggests a strong performance and a commitment to advancing biotechnology and pharmaceutical solutions for government agencies.
Frequently Asked Questions
What does GENENTECH USA, INC do for the federal government?
GENENTECH USA, INC specializes in biotechnology and pharmaceutical solutions, providing services such as research, development, and manufacturing of biopharmaceuticals. The company's core capabilities include advanced biomanufacturing, drug discovery, and clinical research. They contribute to government-funded research and development initiatives, particularly in biotechnology and healthcare.
How much taxpayer money does GENENTECH USA, INC receive?
GENENTECH USA, INC has secured a total of $450.4 million in federal contracts over 10 contracts. The average contract size is $45,036,746, indicating substantial government investment in the company's biotechnology and pharmaceutical solutions.
Is GENENTECH USA, INC good value for taxpayer money?
GENENTECH USA, INC provides significant value to taxpayers through its contributions to government-funded research and development initiatives. The company's expertise in biotechnology and pharmaceuticals ensures that taxpayer money is invested in cutting-edge solutions. However, the lack of detailed performance metrics and recent contract information makes it challenging to fully assess the value proposition. The company's average contract size of $45,036,746 suggests that it secures substantial contracts, which can be beneficial for government agencies seeking specialized services.
How does GENENTECH USA, INC win its contracts?
GENENTECH USA, INC primarily wins its contracts through competitive bidding, with a 100% competitive win rate. The company's strong market position and advanced research and development capabilities enable it to secure substantial contracts with various government agencies, particularly in biotechnology and pharmaceuticals.
What agencies use GENENTECH USA, INC most?
While specific agency relationships are not detailed, GENENTECH USA, INC's diverse portfolio of contracts suggests reliance on various government agencies. The company's focus on biopharmaceuticals and biomanufacturing indicates that it is relied upon by agencies such as the National Institutes of Health (NIH) and the Department of Defense (DoD) for specialized services. However, the lack of detailed information on agency dependencies makes it difficult to assess the extent of reliance on any single agency.
What are the risks of relying on GENENTECH USA, INC?
The lack of recent contracts and detailed performance metrics raises concerns about potential business activity decline. The absence of sole-source awards suggests that the company is not leveraging its position to secure contracts through non-competitive means. The lack of detailed information on agency dependencies makes it challenging to assess potential concentration risks. However, the company's strong competitive position and focus on critical research areas mitigate some of these risks.
How does GENENTECH USA, INC compare to similar contractors?
GENENTECH USA, INC holds a dominant position in specialized areas of biotechnology and pharmaceuticals. The company's strong competitive edge is evident from its 100% competitive win rate and a focus on biopharmaceuticals, biomanufacturing, and drug discovery. Its advanced research and development capabilities position it as a key player in government-funded initiatives, particularly in biotechnology and healthcare. When compared to industry peers, GENENTECH USA, INC is a leading player in its sector, with a strong competitive advantage and a focus on cutting-edge solutions.
Recent Federal Contracts
Genentech USA, Inc has 3 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $60M contract for pharmaceutical preparations to Genentech USA, Inc. | Department of Health and Human Services | $60.0M | N/A |
| HHS awards $45.1M for Tamiflu capsules, with delivery expected by June 2025. | Department of Health and Human Services | $45.1M | N/A |
| HHS awards $37.5M for Xofluza tablets, securing a 2-year supply for public he... | Department of Health and Human Services | $37.5M | N/A |